Linagliptin is a dipeptidyl peptidase-4 inhibitor that reduces blood sugar by increasing insulin and decreasing glucagon production by the pancreas, used to treat diabetes mellitus type 2. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.